ClinicalTrials.gg
TerminatedNCT01736579Updated May 19, 2021Results posted

Long-Term Study of IGIV, 10% in Alzheimer´s Disease

A Phase 3 interventional study of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) in Alzheimer´s Disease, sponsored by Baxalta now part of Shire. Terminated at 1 site in United States. Open to participants aged 51 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated because the first Phase 3 did not demonstrate efficacy on the co-primary endpoints. The known safety profile remained unchanged.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
51 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,512th of 1,609
6 · median 73
Started
2012
with 61 others
Phase 3
188 of 1,940
19 open now
Registered
549th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,512th largest by enrollment of the 1,609 interventional ones that give a count, is one of 62 that started in 2012, is one of 188 in phase 3, and was the 549th registered.

Alzheimer Disease

3,968 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 51 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this long-term study is to provide additional evidence of safety and efficacy of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase 3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701. Participants and investigators will be blinded to dose unless otherwise notified by the sponsor.

03

Conditions studied

  • Alzheimer´s Disease

Browse trials for

04

Who can participate

Ages eligible
51 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Completed 18 months of study treatment and assessments in Baxter precursor study 160701
  • Diagnosis of probable Alzheimer´s Disease (AD)
  • Able to comply with testing and infusion regimen (including adequate corrected visual acuity and hearing ability)
  • Has a caregiver (study partner) who is willing and able to participate

Main Exclusion Criteria:

  • Significant neurological disease other than AD
  • cardiac/cardiovascular problems (e.g. uncontrolled blood pressure, atrial fibrillation, heart disease, clotting disorders, strokes, or recent heart attack)
  • to undergoing MRI (e.g. pacemaker [with the exception of an MRI-compatible pacemaker], severe claustrophobia, ferromagnetic implants such as a metal plate)
  • Specific findings on brain MRI (microhemorrhages, superficial siderosis, vasogenic edema, a macrohemorrhage, major stroke, or multiple lacunae)
  • Active or history of malignancy within 5 years prior to screening with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment
  • Uncontrolled major depression, psychosis, or other major psychiatric disorder(s)
  • Poorly controlled diabetes
  • Serious problems with liver or kidneys
  • Known history of following infusions of human blood or blood components (e.g. human immunoglobulins or human albumin)
  • Current or recent treatment with immunomodulatory therapies (with the exception of immunoglobulin and non-systemic and low-dose systemic )
  • Recent use of drugs or biologics, including those aimed at altering AD progression (with the exception of immunoglobulin)
  • Active immunization for the treatment of AD at any time

There are reasons why it might not be appropriate to participate in this trial. Please contact Medical Information at medinfo@baxter.com for details.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    IGIV, 10% at 0.2 g/kg body weight

    IGIV, 10% at 0.2 g/kg body weight every 2 weeks for up to 3 years, 6 months.

    Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

  • Experimental
    IGIV, 10% at 0.4 g/kg body weight

    IGIV, 10% at 0.4 g/kg body weight every 2 weeks for up to 3 years, 6 months

    Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

Interventions

06

What researchers measure

Primary outcomes

  1. Number and Severity of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: 6 months

  2. Number of Infusions Temporally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: 6 months

  3. Number of Infusions Causally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: 6 months

  4. Number of Infusions Discontinued, Slowed or Interrupted Due to an Adverse Event (AE) or Serious Adverse Event (SAE)

    Time frame: 6 months

Secondary outcomes

  1. Total Score of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog)

    The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at the site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment.

    Time frame: 6 months

  2. Total Score of the Cognitive Subscale of the Severe Impairment Battery (SIB)

    The SIB is a 40-item psychometric assessment that is composed of simple one-step commands combined with gestures. The scoring range is from 0 to 100 with a lower score indicating greater cognitive impairment.

    Time frame: 6 months

  3. Alzheimer's Disease Cooperative Study (ADCS) - Activities of Daily Living (ADL) Inventory (ADCS-ADL/ ADCS-ADL-severe)

    The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.

    Time frame: 6 months

  4. Mini Mental State Examination (MMSE)

    The MMSE is a test for cognitive dysfunction. The test provides a 30-point composite rating for spatial and temporal orientation, verbal recall, simple attention, working memory, naming, repetition, comprehension, writing and constructional abilities. The total score can range from 0 to 30 with a higher score indicating better function.

    Time frame: 6 months

  5. Neuropsychiatric Inventory (NPI) Score

    The NPI is a validated instrument used to assess behavioral psychopathology in Alzheimer's Disease; it evaluates the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.

    Time frame: 6 months

  6. Logsdon Quality of Life in Alzheimer's Disease (QOL-AD)

    The QOL-AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL-AD are associated with a lower quality of life.

    Time frame: 6 months

  7. EQ-5D Questionnaire (Proxy Version)

    EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. The EQ-5D also includes a standard vertical 20 cm visual analogue scale (VAS) ranging from best imaginable health state \[100\] to worst imaginable health state \[0\]. Caregivers are asked to describe how they believe a participant would rate his/her health state that day.

    Time frame: 6 months

  8. Healthcare Resource Utilization Questionnaire (HRUQ)

    The HRUQ determines if there is a difference in healthcare utilization and health-related expenditures, most notably nursing home (ie, skilled nursing facility) admissions, when subjects are treated with study product. This assessment is performed with the primary caregiver. This assessment is descriptive and does not contain specific scores.

    Time frame: 6 months

  9. Caregiver Burden Questionnaire

    The Caregiver burden questionnaires is a self-administered questionnaire that has been developed to measure the emotional, physical, and social impact of caregiving on Alzheimer's Disease caregivers. A Total score is calculated from this measure by summing the responses across the items. The Total score may range from 9-45, with higher scores indicating greater burden.

    Time frame: 6 months

  10. Time to Skilled Nursing Facility Placement

    Time to skilled nursing facility placement is defined as permanent admission to a skilled nursing facility. Time will be defined as the number of months between enrollment into this clinical study and placement in a skilled nursing facility placement.

    Time frame: 6 months

  11. Volumetric MRI

    Volumetric MRI measurements were obtained to assess rate of whole brain atrophy and ventricular enlargement. Additional volumetric measurements may be analyzed when specific hypotheses and methods are defined. Additional volumetric MRI analysis may include (but may not be limited to) one or more of the following: rate of hippocampal atrophy, entorhinal cortical thickness, and/or regional cortical thinning.

    Time frame: 6 months

07

Results

Posted Aug 23, 2016
Limitations and caveats
This study was an extension of study 160701 and was stopped early due to lack of evidence of clinical benefit of IGIV treatment in Alzheimer's Disease patients in Baxalta study 160701. Summary tables available for safety data only.

Participant flow

Enrollment was conducted at one clinical site in the US.

Participant flow — Overall Study
MilestoneIGIV, 10% at 0.2 g/kg Body WeightIGIV, 10% at 0.4 g/kg Body Weight
Started22
Completed00
Not completed22
Withdrew: Termination of study by sponsor22

Outcome measures

PrimaryNumber and Severity of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
6 months
Reported as:
Number · adverse events
Number and Severity of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
adverse eventsIGIV, 10% at 0.2 g/kg Body WeightIGIV, 10% at 0.4 g/kg Body Weight
Non-serious AEs-Mild20
Non-serious AEs-Moderate11
SAEs00
PrimaryNumber of Infusions Temporally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
6 months
Reported as:
Number · infusions
Number of Infusions Temporally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)
infusionsIGIV, 10% at 0.2 g/kg Body WeightIGIV, 10% at 0.4 g/kg Body Weight
Number of Infusions Temporally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)10
PrimaryNumber of Infusions Causally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
6 months
Reported as:
Number · infusions
Number of Infusions Causally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)
infusionsIGIV, 10% at 0.2 g/kg Body WeightIGIV, 10% at 0.4 g/kg Body Weight
Number of Infusions Causally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)11
PrimaryNumber of Infusions Discontinued, Slowed or Interrupted Due to an Adverse Event (AE) or Serious Adverse Event (SAE)
Time frame:
6 months
Reported as:
Number · infusions
Number of Infusions Discontinued, Slowed or Interrupted Due to an Adverse Event (AE) or Serious Adverse Event (SAE)
infusionsIGIV, 10% at 0.2 g/kg Body WeightIGIV, 10% at 0.4 g/kg Body Weight
Number of Infusions Discontinued, Slowed or Interrupted Due to an Adverse Event (AE) or Serious Adverse Event (SAE)00
SecondaryTotal Score of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog)

The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at the site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryTotal Score of the Cognitive Subscale of the Severe Impairment Battery (SIB)

The SIB is a 40-item psychometric assessment that is composed of simple one-step commands combined with gestures. The scoring range is from 0 to 100 with a lower score indicating greater cognitive impairment.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryAlzheimer's Disease Cooperative Study (ADCS) - Activities of Daily Living (ADL) Inventory (ADCS-ADL/ ADCS-ADL-severe)

The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryMini Mental State Examination (MMSE)

The MMSE is a test for cognitive dysfunction. The test provides a 30-point composite rating for spatial and temporal orientation, verbal recall, simple attention, working memory, naming, repetition, comprehension, writing and constructional abilities. The total score can range from 0 to 30 with a higher score indicating better function.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryNeuropsychiatric Inventory (NPI) Score

The NPI is a validated instrument used to assess behavioral psychopathology in Alzheimer's Disease; it evaluates the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryLogsdon Quality of Life in Alzheimer's Disease (QOL-AD)

The QOL-AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL-AD are associated with a lower quality of life.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryEQ-5D Questionnaire (Proxy Version)

EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. The EQ-5D also includes a standard vertical 20 cm visual analogue scale (VAS) ranging from best imaginable health state \[100\] to worst imaginable health state \[0\]. Caregivers are asked to describe how they believe a participant would rate his/her health state that day.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryHealthcare Resource Utilization Questionnaire (HRUQ)

The HRUQ determines if there is a difference in healthcare utilization and health-related expenditures, most notably nursing home (ie, skilled nursing facility) admissions, when subjects are treated with study product. This assessment is performed with the primary caregiver. This assessment is descriptive and does not contain specific scores.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryCaregiver Burden Questionnaire

The Caregiver burden questionnaires is a self-administered questionnaire that has been developed to measure the emotional, physical, and social impact of caregiving on Alzheimer's Disease caregivers. A Total score is calculated from this measure by summing the responses across the items. The Total score may range from 9-45, with higher scores indicating greater burden.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryTime to Skilled Nursing Facility Placement

Time to skilled nursing facility placement is defined as permanent admission to a skilled nursing facility. Time will be defined as the number of months between enrollment into this clinical study and placement in a skilled nursing facility placement.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryVolumetric MRI

Volumetric MRI measurements were obtained to assess rate of whole brain atrophy and ventricular enlargement. Additional volumetric measurements may be analyzed when specific hypotheses and methods are defined. Additional volumetric MRI analysis may include (but may not be limited to) one or more of the following: rate of hippocampal atrophy, entorhinal cortical thickness, and/or regional cortical thinning.

Time frame:
6 months

No measurements were reported for this outcome.

Adverse events

Collected over Throughout the study period (6 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGIV, 10% at 0.2 g/kg Body Weight—0/2 (0%)1/2 (50%)
IGIV, 10% at 0.4 g/kg Body Weight—0/2 (0%)1/2 (50%)
Most frequent other events
Most frequent other events
EventIGIV, 10% at 0.2 g/kg Body WeightIGIV, 10% at 0.4 g/kg Body Weight
Infusion Site PainGeneral disorders1/20/2
Tooth InfectionInfections and infestations1/20/2
Blood Pressure IncreasedInvestigations1/20/2
UrticariaSkin and subcutaneous tissue disorders0/21/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IGIV, 10% at 0.2 g/kg Body WeightIGIV, 10% at 0.4 g/kg Body WeightTotal
<=18 years000
Between 18 and 65 years000
>=65 years224
Sex: Female, Male
Sex: Female, Male(Participants)IGIV, 10% at 0.2 g/kg Body WeightIGIV, 10% at 0.4 g/kg Body WeightTotal
Female112
Male112
08

Study locations

1 site
  • Rochester, New York, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2012 to primary completion in Jun 2013, 6 months.

Results were first posted in Aug 2016, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2012
First posted
Nov 29, 2012
StartActual
Nov 29, 2012
Primary completionActual
Jun 4, 2013
CompletionActual
Jun 4, 2013
Results first posted
Aug 23, 2016
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01736579
Responsible party
Sponsor
First posted
Nov 29, 2012
Start date
Nov 29, 2012
Primary completion
Jun 4, 2013
Completion
Jun 4, 2013
Results posted
Aug 23, 2016
Last update
May 19, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion